Aggregator

Cerebral small vessel disease (SVD) is a leading cause of stroke and dementia and yet is often an incidental finding in aged patients due to the inaccessibility of brain vasculature to imaging. Animal models are important for modelling the development and progression of SVD across the lifespan. In humans, reduced FOXF2 is associated with an increased stroke risk and SVD prevalence in humans. In the zebrafish, foxf2 is expressed in pericytes and vascular smooth muscle cells and is involved in...

Increasing health inequalities among older adults globally illustrate the urgent need for effective interventions. Socio-economic position (SEP), which reflects an individual's social and economic standing, may affect healthy ageing through various life course mechanisms. However, longitudinal associations between life course SEP and healthy ageing as a multidimensional construct remain unclear. We conducted a comprehensive systematic review of longitudinal studies investigating the associations...

Retinal age gap (RAG)-the difference between retina-predicted age and chronological age-indicates biological ageing that has been linked to the risk of mortality and chronic disease. We aimed to identify risk factors associated with higher RAG in an Australian population. This cross-sectional study included 5107 participants from the Busselton Healthy Ageing Study (BHAS), a Western Australian community-based cohort. Retinal age was estimated using a validated deep-learning model applied to...

Junior researchers are more likely to embrace preprints; grant reviewers and hiring committees express doubts

The biomedical research agency says trainees in its labs are not “employees”

Alzheimer's disease (AD) is the leading cause of dementia and is characterized by progressive amyloid accumulation followed by tau-mediated neurodegeneration. Despite advances in anti-amyloid immunotherapies, important limitations remain, highlighting the need for new therapeutic strategies. Here, we introduce anti-amyloid chimeric antigen receptors expressed in astrocytes (CAR-A) and validate their function in vitro. We show that two CAR-A designs reduce amyloid and associated pathology after...

Genetically altered astrocytes reduce a cardinal pathological feature of Alzheimer's disease.